Table 1:
Patient, disease, and treatment characteristics.
| n | SD / % | |
|---|---|---|
|
| ||
| Total | 470 | |
|
|
||
| Age (SD) | 61.66 | (9.61) |
|
| ||
| Sex (%) | 420 | (89%) |
| 50 | (11%) | |
|
| ||
| T stage (%) | ||
| T1 | 145 | (31%) |
| T2 | 169 | (36%) |
| T3 | 67 | (14%) |
| T4 | 57 | (12%) |
| T0 | 32 | (7%) |
|
| ||
| N stage (%) | ||
| N0 | 42 | (9%) |
| N1 | 127 | (27%) |
| N2a | 33 | (7%) |
| N2b | 193 | (41%) |
| N2c | 67 | (14%) |
| N3 | 8 | (2%) |
|
| ||
| p16/HPV status (%) | ||
| Negative | 31 | (7%) |
| Positive | 429 | (91 %) |
| Unknown | 10 | (2%) |
|
| ||
| Performance score (%) | ||
| Unknown | 18 | (4%) |
| 0 | 329 | (70%) |
| 1 | 117 | (25%) |
| 2 | 5 | (1%) |
| 3 | 1 | (0%) |
|
| ||
| Tumor site (%) | ||
| Tonsil | 201 | (43%) |
| Base of tongue | 225 | (48%) |
| Pharyngeal wall | 4 | (1%) |
| Soft palate | 4 | (1%) |
| Multiple sites | 8 | (2%) |
| Unknown primary | 28 | (6%) |
|
| ||
| Treatment (%) | ||
| Concurrent chemoRT | 329 | (7O%) |
| Induction + concurrent chemoRT | 66 | (14%) |
| RT alone | 75 | (16%) |